RE:RE:RE:RE:RE:RE:Technical420 reportLemoyne....you've certainly turned wet blanket dear boy....hopefully you're not too underwater....I know I am and am pissed, but geez....it's not like there hasn't been a global cataclysm that has hit the pause button on damn near everything except vaccine research and national debt spending....
Sure, did they say they were ramping up international stuff end of this year, beginning of next, you bet....did those predictions take a shyte kick because of covid stuff...probably....will this recover by next Q...who knows....but doubtful.
But the BoD wants someone different to take the reins and take this next step....that, more than anything else, will be the most telling on whether we continue to hold the bags or not....IMO
Lemoyne wrote: They twist the words to make it appear important. ie: I used information from tech420 articles (CGC being biggest client, posted during Q3) to try and make estimates. But CGC is biggest client for peanuts amount.
They keep pushing ramp up back. Remember: they said revenues would ramp up during backhalf of 2020, now its backhalf of 2021. Some of their press releases had intl sales in EU and LATAM in Q3/Q4 2020...
Competition wise, Althea (australia) announced they received registration for extract products in germany last month.
I doubt LABS manages to make Stada sales in feb 2021 as Pat said during Q3 cc.
There is a reason shorts kept piling on despite Q3 crash. I thought short float would diminish after Q3 drop but it actually went up...
So yeah, on top of Q4 being a coin toss, Q1 might not be a significant improvement.